Sliptin-M Tablet 50 mg + 500 mg is a combination oral antihyperglycemic medication containing Sitagliptin and Metformin Hydrochloride, formulated for the effective management of type 2 diabetes mellitus in adults. This combination brings together the complementary actions of two proven antidiabetic agents to improve glycemic control:

• Sitagliptin (50 mg) – a Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances incretin hormone activity, increasing insulin secretion and reducing glucagon release in a glucose-dependent manner.

• Metformin Hydrochloride (500 mg) – a biguanide that decreases hepatic glucose production, improves peripheral glucose uptake, and enhances insulin sensitivity.

Sliptin-M is indicated for adults who cannot achieve adequate blood glucose control with diet and exercise alone and for patients requiring combination therapy to manage hyperglycemia effectively.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Sitagliptin 50 mg

• Metformin Hydrochloride 500 mg

Mechanism of Action

Sitagliptin Component:

• Inhibits the DPP-4 enzyme, preventing the degradation of incretin hormones GLP-1 and GIP

• Increases postprandial insulin secretion from pancreatic beta cells

• Suppresses glucagon secretion, reducing hepatic glucose output

• Action is glucose-dependent, minimizing hypoglycemia risk

Metformin Component:

• Reduces hepatic gluconeogenesis, lowering fasting blood glucose

• Increases insulin sensitivity in peripheral tissues, enhancing glucose uptake

• Improves glycemic control without stimulating insulin secretion, also helping with weight management

Together, these mechanisms address both fasting and postprandial hyperglycemia, providing a synergistic effect for comprehensive glucose control.

Indications

Sliptin-M Tablet 50 mg + 500 mg is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled with diet and exercise

• Patients needing dual-action therapy for better glycemic control

• Combination therapy for patients already on metformin or sitagliptin monotherapy who require enhanced blood sugar management

• Those seeking a convenient once- or twice-daily oral dosing regimen

Dosage and Administration

• Recommended starting dose: 1 tablet once or twice daily, with meals, to minimize gastrointestinal side effects

• Swallow the tablet whole; do not crush or chew

• Consistent timing of doses is essential for optimal blood glucose control

• Dose adjustments may be required in patients with renal impairment

• Regular blood glucose monitoring is recommended

Benefits

• Effective glycemic control by combining two complementary mechanisms

• Improves fasting and postprandial blood glucose levels

• Minimizes hypoglycemia due to glucose-dependent insulin action

• Can aid in weight management due to metformin’s insulin-sensitizing effect

• Convenient single tablet combination therapy enhances patient adherence

• Supports long-term metabolic health and reduces diabetes-related complications

Precautions

• Not suitable for type 1 diabetes or diabetic ketoacidosis

• Monitor renal and hepatic function before and during therapy

• Caution in patients with cardiovascular or gastrointestinal disorders

• Use during pregnancy or lactation only if benefits outweigh risks

• Maintain diet and exercise regimen alongside medication

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects:

• Gastrointestinal disturbances (nausea, diarrhea, abdominal discomfort)

• Headache

• Nasopharyngitis

Rare but serious side effects:

• Lactic acidosis (rare but serious risk with metformin in patients with renal impairment)

• Pancreatitis (persistent abdominal pain)

• Hypersensitivity reactions, including rash, swelling, or hives

Storage

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.

Sliptin-M Tablet 50 mg + 500 mg offers a dual mechanism approach to type 2 diabetes management, combining improved insulin response, reduced hepatic glucose output, and enhanced peripheral glucose uptake for effective and safe long-term glycemic control.